Google Cloud has unveiled two new AI-powered tools designed to accelerate drug discovery and enhance precision medicine in the biotech and pharmaceutical sectors.
The first tool, known as the Target and Lead Identification Suite, assists companies in predicting and comprehending protein structures, a fundamental aspect of drug development. The suite employs AlphaFold2, a machine learning model developed by Google, to accurately forecast protein structures and identify molecules that interact with proteins for potential drug development.
The second tool, the Multiomics Suite, aids researchers in managing and analysing large volumes of genomic data, offering the necessary infrastructure to extract meaningful insights and facilitate scientific breakthroughs.
These innovations aim to reduce the time and financial resources required to bring new medications to market, addressing a long-standing challenge in the biopharma industry. Several notable companies, including Pfizer, Cerevel Therapeutics, and Colossal Biosciences, have already adopted these tools to enhance their operations.
These new developments mark Google’s latest advancement in the AI arms race, where tech companies are competing to dominate a market that analysts believe could someday be worth trillions.
The new suites will save companies a “statistically significant” amount of time and money throughout the drug development process, said Shweta Maniar, Google Cloud’s global director of life sciences strategy and solutions.
Read the original article here.